Singapore: Amgen is going to construct its new manufacturing unit in the Tuas Biomedical Park area, in Singapore. The firm is expected to invest close to $200 million over the next few years in order to develop the innovative new facility.

The plant will initially focus on expanding Amgen's manufacturing capability for monoclonal antibodies and will have the ability to manufacture both clinical and commercial products.

Ms Madhu Balachandran, executive vice president, operations, Amgen, said that, "Amgen is pleased to be planning for a new world-class facility in Singapore as part of our global expansion strategy. Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment."

Construction of the manufacturing facility is expected to start during the next couple of months. Amgen will recruit both new and experienced staff and is currently partnering with local universities to hire for a number of positions in manufacturing and quality.